Literature DB >> 8739962

Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up.

M Ruiz1, T Pampols, M Girós.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8739962     DOI： 10.1007/bf01799426

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  14 in total

1.  A comparison of erythrocytes, lymphocytes and blood plasma as samples in fatty acid analysis for the diagnosis of adrenoleukodystrophy.

Authors:  Y Antoku; Y Ohtsuka; H Nagara; T Sakai; K Tsukamoto; H Iwashita; I Goto
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

2.  Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels.

Authors:  W B Rizzo; M W Phillips; A L Dammann; R T Leshner; S S Jennings; J Avigan; V K Proud
Journal:  Ann Neurol       Date:  1987-03       Impact factor: 10.422

3.  Galactolipid fatty acid composition in adrenoleukodystrophy.

Authors:  R B Ramsey; N L Banik; A N Davison
Journal:  J Neurol Sci       Date:  1977-05       Impact factor: 3.181

4.  Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy.

Authors:  S Zierz; R Schröder; C J Unkrig
Journal:  Clin Investig       Date:  1993-10

Review 5.  Adrenoleukodystrophy: phenotypic variability and implications for therapy.

Authors:  H W Moser; A B Moser; K D Smith; A Bergin; J Borel; J Shankroff; O C Stine; C Merette; J Ott; W Krivit
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

6.  Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters.

Authors:  G C Korenke; D H Hunneman; J Kohler; S Stöckler; K Landmark; F Hanefeld
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

7.  A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.

Authors:  P Aubourg; C Adamsbaum; M C Lavallard-Rousseau; F Rocchiccioli; N Cartier; I Jambaqué; C Jakobezak; A Lemaitre; F Boureau; C Wolf
Journal:  N Engl J Med       Date:  1993-09-09       Impact factor: 91.245

8.  Dietary treatment of adrenoleukodystrophy.

Authors:  S Suzuki; T Kobayashi; I Goto; Y Kuroiwa
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

9.  Covalent modification of proteins by arachidonate and eicosapentaenoate in platelets.

Authors:  L Muszbek; M Laposata
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

10.  Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination.

Authors:  C Theda; A B Moser; J M Powers; H W Moser
Journal:  J Neurol Sci       Date:  1992-07       Impact factor: 3.181
View more
  1 in total

1.  Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.

Authors:  Marion Deon; Mariana Pires Garcia; Angela Sitta; Alethéa G Barschak; Daniella M Coelho; Graziela O Schimit; Maiara Pigatto; Laura B Jardim; Moacir Wajner; Roberto Giugliani; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.